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Abstract
Background—Alzheimer’s disease (AD) research progress is impeded due to participant
recruitment challenges. This study seeks to better understand, from the perspective of individuals
engaged in clinical trials (CTs), research motivations.
Methods—Participants, or their caregivers, from AD treatment and prevention CTs were
surveyed about research motivators.
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Results—The eighty-seven respondents had a mean age of 72.2, were predominantly Caucasian,
55.2% were male, and 56.3% had cognitive impairment. An overwhelming majority rated the
potential to help themselves or a loved one and the potential to help others in the future as
important motivators. Relatively few respondents were motivated by free healthcare, monetary
rewards, or to make others happy.
Conclusions—Recruitment efforts should focus on the potential benefit for the individual, their
loved ones, and others in the future rather than free healthcare or monetary rewards.
Keywords
Clinical Trials; Motivation; Recruitment
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Introduction
Today over five million Americans have Alzheimer’s disease (AD) and it is estimated that
someone develops AD every 67 seconds in the United States. It is expected that by 2050
there will be between 11 and 16 million individuals living with AD in the United States if
we do not experience any breakthroughs in therapeutic development [1]. While symptomatic
treatments are currently available, at present there are no options for disease modifying
therapies that might alter the disease course. Researchers are working to develop new
medications or strategies to prevent or treat AD, but recruitment of research participants
remains a challenge [2].
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Recruitment has historically been one of the largest impediments to successful clinical trials
[3]. Currently, less than one third of trials achieve their initial recruitment target and even
among those trials that do reach their desired participation numbers, half require a prolonged
recruitment period [4]. Improving the science behind recruitment for AD clinical trials is
imperative for advancing the rate of scientific discoveries for prevention and treatment [5].
Challenges to the recruitment of AD clinical trials include fear of medication side-effects,
perceived lack of personal benefit of placebo-controlled trials and in prevention studies, fear
over invasive procedures, the requirement of a study partner, logistical concerns such as time
and travel, general skepticism towards research, and for treatment focused trials the underdiagnosis of AD and mild cognitive impairment [6]. While knowledge of these challenges
can help inform study design to make trials more appealing to participants, addressing
barriers does not guarantee that someone will chose to get involved. Much of the existing
research exploring recruitment for clinical trials focuses on hypothetical research studies
rather than real research participants [7]. In order to truly understand how to get individuals
involved we need to better understand the motivations of participants who make the decision
to enroll. Accordingly the purpose of this study is to better understand, from the perspective
of individuals actually engaged in AD prevention and treatment clinical trials, motivations
for research participation.
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Methods
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Surveys were mailed to 171 participants or their study partners from seven different AD
prevention or treatment clinical trials being conducted at a single AD center. These studies
included two for individuals with AD, two for individuals with mild cognitive impairment
(MCI) or AD, one only for individuals with mild cognitive impairment, one for individuals
with normal cognition or mild cognitive impairment, and one only for those with normal
cognition. Surveys were mailed to active study participants, those who enrolled in one of the
studies did not pass the screening process, and those who withdrew from one of the studies
but agreed to be contacted about additional research. The surveys included a series of
questions about potential motivators for research participation (e.g. to help themselves, to
help others, to get free healthcare) and participants were asked to rate each item on a fivepoint Likert scale from “not at all important” to “extremely important”. Responses were
dichotomized to distinguish participants who rated a motivator as somewhat or extremely
important from those that did not view that motivator as important. Analysis involved
descriptive statistics to describe characteristics of the sample. Independent samples t-tests
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and chi-square tests were done to explore differences based on group characteristics (e.g.
respondents and non-respondents, normal and impaired cognition, women and men). In
addition, Mann-Whitney tests were used to examine the non-dichotomized ordinal
responses.

Results
Surveys were completed by 87 of the 171 respondents, representing a 51.2% response rate.
There were no significant differences between respondents and non-respondents in terms of
cognitive status, sex, race, or age (see Table 1).
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The majority of surveys were completed by the research participant themselves (78.2%),
with an average age of 72.4 (range of 54.6-89.8), just over half were male (55.2%), most
were Caucasian (87.4%), and just over half were in a study for participants with cognitive
impairment (MCI or AD) (56.3%) (See Table 2).
There were no significant differences between those with normal and impaired cognition in
terms of sex, race, or age.
An overwhelming majority of respondents rated the potential to help themselves or a loved
one (92.9%) and the potential to try to help others in the future (96.5%) as important
motivators for research participation. Relatively few respondents were motivated by free
healthcare services (23%) or monetary rewards (4.6%). A minority of participants indicated
being motivated to make a family member (26.7%) or doctor (15.1%) happy (see Figure 1).

Author Manuscript

Women (38.5%) were significantly more likely than men (17.0%) to report participating in
research to make family members happy, p=.025. There were no significant differences
between those with normal and impaired cognition for any of the potential research
motivators. There were also no significant age or racial differences in motivational factors
based on whether the participant or study partner completed the survey.
Using Mann-Whitney statistics to explore the ranked responses, there were no statistically
significant differences in motivational factors for participating based on the cognitive status
or the race of the participant. Consistent with the dichotomized results, women rated the
likelihood of participating to make a family member happy as more important than men,
Mann–Whitney U = 697.0, n1 =47 n2 = 39, P =.049, two-tailed. Women also rated the
likelihood of participating to make a doctor happy as more important than men, Mann–
Whitney U = 668.5, n1 =47 n2 = 39, P =.025, two-tailed (see Figure 2).
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Finally, those who completed the survey themselves rated the desire to help themselves as
lower than those who completed the survey on behalf of the research participant, Mann–
Whitney U = 364.0, n1 =66 n2 = 16, P =.024 two-tailed.

Discussion
The results of this study suggest that recruitment efforts for AD prevention and treatment
clinical trials should focus on the potential benefit for the individual, their loved ones, and
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others in the future rather than personal benefits such as free healthcare or monetary
rewards. Efforts should be made to convey the message that research has the potential to
help not only the individual involved, but also to help others in the future. The potential to
help others in the future may be a particularly critical message to convey as many AD
prevention and treatment research studies provide no clear immediate personal benefit, yet
still entail invasive study procedures such as spinal fluid collection.
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In addition, these findings suggest that future recruitment efforts should explore ways to
leverage social awareness and the need to promote research participation, particularly among
women. Given that most AD prevention and treatment research includes a study partner,
efforts to engage various care partners and life companions, including spouses, adult
children, partners or friends, and promote understanding of the importance of research
participation across these individuals and across ages and racial groups may strengthen both
recruitment and retention efforts [8]. Potential study partners may encourage their loved
ones to participate in research based on the hope it will help their loved one directly. While
the potential benefits of the treatments or interventions under investigation cannot be
guaranteed, efforts to promote additional recruitment could highlight other possible benefits
that participants may receive, including the close medical monitoring of individuals engaged
in research studies and the personal fulfillment of playing a valuable role in the search for
better ways to prevent or treat AD.
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While this research was limited by a small sample size, one strength of this study is that
responses come from research participants actually engaged in AD research, not from those
being asked about hypothetical reasons they may choose to participate in research studies.
The small sample size, however, may have prevented us from detecting differences in
motivation for research engagement between different groups of participants. Future
research should involve a larger, multi-site sample to explore whether motivations to
participate in AD research may differ between participants and caregivers. Identifying
potential differences in motivation along the cognitive continuum of participants may help to
craft messages and target recruitment materials more effectively. While prior research has
indicated how sociodemographic factors impact clinical trial eligibility, more work is needed
to understand how these factors relate to willingness to participate [9]. Future research
should gather a wider range of sociodemographic factors such as educational attainment and
social support to better understand the nuances of research engagement. In addition, a larger
sample should focus on expanding knowledge about the motivations for research
participation among minority populations, who are largely underrepresented in AD research
[10].
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Figure 1.

Motivations for Participation – Self and Other Respondents
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Figure 2.

Gender Differences in Research Motivations
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Characteristics of Respondents and Non-Respondents
Respondents
n=87, n(%)

Non-Respondents
n=83, n(%)

Normal

38 (43.7)

34 (41.0)

Impaired

49 (56.3)

49 (59.)

Male

48 (55.2)

39 (47.0)

Female

39 (44.8)

44 (53.0)

Caucasian

76 (87.4)

71 (85.5)

Other

11 (12.6)

12 (14.5)

72.4 (7.4)

73.2 (7.2)

Cognitive Status

Sex

Race
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Age, mean (SD)
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Respondent Characteristics
Normal Cognition
n=38, n(%)

Impaired Cognition
n=49, n(%)

All Respondents
n=87, n(%)

Participant

37 (97.4)

31 (63.3)

68 (78.2)

Study Partner

1 (2.6)

15 (30.6)

16 (18.4)

Unknown

0

3 (6.1)

3 (3.4)

Male

20 (52.6)

28 (57.1)

48 (55.2)

Female

18 (47.4)

21 (42.9)

39 (44.8)

Caucasian

32 (84.2)

44 (89.8)

76 (87.4)

Other

6 (15.8)

5 (10.2)

11 (12.6)

72.2 (4.5)

72.5 (9.1)

72.4 (7.4)

Respondent

Sex

Race
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Age, mean (SD)
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